A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement

Simply Wall St.03-28 23:07

Monte Rosa Therapeutics (GLUE) has moved into focus after signing a supply agreement with Johnson & Johnson to evaluate MRT-2359 plus ERLEADA in a planned Phase 2 trial for metastatic castration-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622738257?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-28 23:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622738257","market":"sg","top_or_hot":-1,"title":"A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement","media":"Simply Wall St.","content":"<div>\n<p>Monte Rosa Therapeutics (GLUE) has moved into focus after signing a supply agreement with Johnson & Johnson to evaluate MRT-2359 plus ERLEADA in a planned Phase 2 trial for metastatic castration-...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/a-look-at-monte-rosa-therapeutics-glue-valuation-after-johns\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-28 23:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/a-look-at-monte-rosa-therapeutics-glue-valuation-after-johns><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Monte Rosa Therapeutics (GLUE) has moved into focus after signing a supply agreement with Johnson & Johnson to evaluate MRT-2359 plus ERLEADA in a planned Phase 2 trial for metastatic castration-...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/a-look-at-monte-rosa-therapeutics-glue-valuation-after-johns\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/a-look-at-monte-rosa-therapeutics-glue-valuation-after-johns","article_id":"2622738257","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/a-look-at-monte-rosa-therapeutics-glue-valuation-after-johns","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622738257","pubTimestamp":1774710427,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Monte Rosa Therapeutics (GLUE) has moved into focus after signing a supply agreement with Johnson & Johnson to evaluate MRT-2359 plus ERLEADA in a planned Phase 2 trial for metastatic castration-resistant prostate cancer.\nSee our latest analysis for Monte Rosa Therapeutics.\nAlongside the Johnson & Johnson supply agreement and fresh MRT-2359 data, Monte Rosa’s share price has eased recently. The stock has a 30 day share price return of 15% and a 90 day share price return decline of 11%. At the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","GLUE":"Monte Rosa Therapeutics","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","JNJ":"强生","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4139":"生物科技","MRT":"Marti Technologies Inc.","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","BK4504":"桥水持仓","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4588":"碎股","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD"},"translate_title":"强生MRT-2359试验供应协议后Monte Rosa Therapeutics(GLUE)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRT":1.5,"GLUE":1.5,"DCF":1,"JNJ":1.5},"content_text":"Monte Rosa Therapeutics (GLUE) has moved into focus after signing a supply agreement with Johnson & Johnson to evaluate MRT-2359 plus ERLEADA in a planned Phase 2 trial for metastatic castration-resistant prostate cancer. See our latest analysis for Monte Rosa Therapeutics. Alongside the Johnson & Johnson supply agreement and fresh MRT-2359 data, Monte Rosa’s share price has eased recently. The stock has a 30 day share price return of 15% and a 90 day share price return decline of 11%. At the same time, the 1 year total shareholder return of about 3x and 3 year total shareholder return of roughly 2x point to earlier enthusiasm that is now being reassessed as new trial and financing updates come through. If this kind of biotech catalyst has your attention, it could be worth widening your watchlist to other precision medicine names using the Simply Wall St screener for 34 healthcare AI stocks With Monte Rosa trading at US$15.38 and an analyst target of US$32.33, plus an indicated intrinsic discount of about 68%, the key question is whether the recent pullback signals an opportunity or if the market already reflects future growth. AdvertisementPrice-to-Sales of 10x: Is it justified? Monte Rosa trades on a P/S of about 10x, which lines up closely with the US biotech industry average of 10.8x but sits far above its own estimated fair P/S of 1.3x. The P/S multiple compares the company’s market value with its revenue. This can be useful for early-stage or unprofitable biotech names where earnings are still negative. With Monte Rosa reporting revenue of about $123.7m and a net loss of $38.6m, investors appear to be focusing more on future potential than current profitability. However, the gap between the current 10x P/S and the estimated fair P/S of 1.3x is wide. This suggests the market price builds in expectations that exceed what the fair ratio model implies. If sentiment or assumptions around revenue growth and commercialization prospects cool, that gap is one area where valuation could compress toward the level the fair ratio signals. Explore the SWS fair ratio for Monte Rosa Therapeutics Result: Price-to-sales of 10x (OVERVALUED) However, investors also need to weigh the ongoing net loss of US$38.6m and recent share price declines, which could signal sensitivity to future trial or funding news. Find out about the key risks to this Monte Rosa Therapeutics narrative. Another View: DCF Points the Other Way If the 10x P/S ratio suggests Monte Rosa is expensive, the SWS DCF model sends a very different signal. With the shares at $15.38 and the model’s future cash flow value at $48.17, the stock screens as undervalued on this method. Which lens do you trust more when the signals clash? Look into how the SWS DCF model arrives at its fair value. GLUE Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Monte Rosa Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 61 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Mixed signals so far, with strong potential set against clear risks, mean this story is still wide open. Move quickly, review the underlying data, and weigh the 3 key rewards and 5 important warning signs. Looking for more investment ideas? If Monte Rosa is on your radar, do not leave it there alone. Use focused stock lists to spot other opportunities that could fit your style and goals.  Hunt for potential value gaps by reviewing companies that pass the 61 high quality undervalued stocks and see which names stand out on your watchlist. Prioritise resilience by checking stocks highlighted in the 67 resilient stocks with low risk scores and focus on businesses with lower overall risk profiles. Target quality with strong fundamentals through the solid balance sheet and fundamentals stocks screener (39 results) and build a shortlist that looks sturdier across market cycles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622738257","isCrawlerRequest":true}